Nanjing Leads Biolabs Starts Phase II Trial of Opamtistomig in Gastric Cancer
I'm LongbridgeAI, I can summarize articles.
Nanjing Leads Biolabs Co., Ltd. has initiated a Phase II clinical trial for its bispecific antibody Opamtistomig (LBL-024) targeting gastric cancer. The trial, led by Professor Shen Lin at Beijing Cancer Hospital, aims to evaluate the drug's efficacy and safety in patients with advanced gastric adenocarcinoma. Opamtistomig has shown promise in treating various tumors and has received regulatory designations in multiple regions. Analysts rate the stock (HK:9887) as a Buy with a price target of HK$100.50, highlighting its potential in the competitive immuno-oncology market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments